title: Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.
authors: Keiran S M
authors: KS
authors: Smalley
authors: Andrew E
authors: AE
authors: Aplin
authors: Keith T
authors: KT
authors: Flaherty
authors: Christoph
authors: C
authors: Hoeller
authors: Anja K
authors: AK
authors: Bosserhoff
authors: Nikolas K
authors: NK
authors: Haass
authors: Marcus
authors: M
authors: Bosenberg
authors: Antoni
authors: A
authors: Ribas
authors: Raymond
authors: R
authors: Barnhill
authors: Ragini
authors: R
authors: Kudchadkar
authors: Jane L
authors: JL
authors: Messina
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008511:Medicine; D008545:Melanoma / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000556:secondary; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf